Lantheus Holdings, Inc. $LNTH Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. cut its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 3.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,000,689 shares of the medical equipment provider's stock after selling 242,573 shares during the period. Vanguard Group Inc. owned approximately 10.22% of Lantheus worth $683,267,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Lantheus by 3.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,084 shares of the medical equipment provider's stock valued at $1,162,000 after acquiring an additional 400 shares in the last quarter. State of Alaska Department of Revenue raised its holdings in Lantheus by 2.7% in the 1st quarter. State of Alaska Department of Revenue now owns 8,142 shares of the medical equipment provider's stock valued at $794,000 after acquiring an additional 215 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Lantheus by 12,517.1% during the 1st quarter. GAMMA Investing LLC now owns 128,442 shares of the medical equipment provider's stock valued at $12,536,000 after acquiring an additional 127,424 shares during the period. Cerity Partners LLC grew its holdings in shares of Lantheus by 12.7% during the 1st quarter. Cerity Partners LLC now owns 11,709 shares of the medical equipment provider's stock worth $1,143,000 after purchasing an additional 1,323 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its position in shares of Lantheus by 1,196.4% in the first quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider's stock worth $32,817,000 after purchasing an additional 310,301 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on LNTH shares. William Blair reaffirmed a "market perform" rating on shares of Lantheus in a research report on Wednesday, July 16th. JMP Securities cut their price target on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a report on Thursday, August 7th. Truist Financial set a $63.00 price objective on shares of Lantheus and gave the company a "hold" rating in a research note on Monday, August 11th. Mizuho lowered their price objective on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday, August 7th. Finally, Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $105.50.

Lantheus Price Performance

Shares of Lantheus stock traded up $0.28 during trading on Monday, hitting $54.46. 322,194 shares of the stock traded hands, compared to its average volume of 1,152,911. The firm's fifty day moving average is $73.83 and its 200-day moving average is $85.38. The stock has a market cap of $3.70 billion, a price-to-earnings ratio of 14.43 and a beta of 0.14. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $118.21. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $1.57 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.08). The firm had revenue of $378.05 million for the quarter, compared to analysts' expectations of $389.69 million. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The business's quarterly revenue was down 4.1% compared to the same quarter last year. During the same period in the prior year, the business posted $1.80 EPS. Research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Activity at Lantheus

In related news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director directly owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.00% of the stock is owned by company insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.